02367 News
CMSI Lowers GIANT BIOGENE Rating to Neutral and Reduces Target Price to HKD34.5
M Stanley Lowers GIANT BIOGENE (02367.HK) Price Target to $42, Anticipates Boost in Sales from Enhanced Marketing Efforts
UBS Lowers GIANT BIOGENE (02367.HK) Rating to Neutral and Reduces Price Target to $39.5
HSBC Research Lowers GIANT BIOGENE's Target Price to HKD46.4, Maintains Buy Rating
CICC Lowers GIANT BIOGENE's Target Price to HKD56, Remains Positive on Medium- to Long-Term Growth Prospects
CMBI Lowers Price Target for GIANT BIOGENE (02367.HK) to $53.89, Maintains Buy Rating
CICC Optimistic About GIANT BIOGENE's Long-Term Growth Prospects; Anticipates Product Line Expansion by 2026
Citi Reduces Target Price for GIANT BIOGENE to HKD44.6, Maintains Buy Rating
02367 Events
No data
02367 Monitor News
No data
02367 Earnings Analysis